Startups

Aerska logo

Aerska

Aerska develops RNA medicines for neurological diseases. Its antibody-oligonucleotide conjugate platform uses brain shuttle technology to deliver RNA interference therapeutics across the blood-brain barrier and silence disease-associated genes. Its initial research focuses on genetically driven forms of Alzheimer’s and Parkinson’s disease. The company is headquartered in Dublin, with research operations in London and a Boston site announced in June 2026; its platform remains in development.

Founded 2025

Team

Alex BrunickiAlex BrunickiBoard Member
Alex ColvilleBoard Member
Andrew CreganSenior Director, Finance and Administration
Andy BestPrincipal Scientist, siRNA Lead Development
Arno de WildeBoard Member
Christine EsauAdvisory Board Member
Dave HardwickeDirector, Head of Business Development, Co-founder
David CoughlanVP, Head of Early Development
Dominic WalshAdvisory Board Member
Duygu YilmazSenior Director, RNA Therapeutics Discovery and Translational Science
Eugene KimIntellectual Property
Helen CrehanPrincipal Scientist, Translational Pharmacology
Hyoungseok JuDirector, Discovery Project
Ian HugginsSenior Director, Delivery Sciences
Ines MateusSenior Scientist I
Itziar CanamasasBoard Member
Jack O’MearaChief Executive Officer, Co-founder and Board Member
Jayesh MajithiyaDirector, Translational Medicine
Jemimah Keren BungabongOperations Associate
Jessica McDonaldSenior Director, Program Management & Scientific Operations
Lalanti VenkatSenior Manager, Business Development and Strategy
Laura Sepp-LorenzinoAdvisory Board Member
Lisa Taylor AshBoard Member
Lynne HughesLynne HughesAdvisory Board Member
Mark WoltersAdvisory Board Member
Marta DragoshiSenior Manager, Office of the CEO
Michael PerkintonVP, Head of Research
Nienke VrienzenDirector, CMC Strategy
Ollie KingSenior Scientist I
Peter HoehnAdvisory Board Member
Philip ScheltensPhilip ScheltensBoard Observer
Robyn McAdamPrincipal Scientist
Sam HandelmanPrincipal Scientist, Clinical Informatics & Data Science
Saskia ReibePrincipal Scientist, Computational siRNA Lead Development
Stuart MilsteinChief Platform Officer, Co-founder
Uli StilzUli StilzBoard Member

Investments